 Genprex, Inc. NASDAQ:GNPX revealed that the US Food and Drug Administration FDA granted Fast Track designation to the companys lead drug candidate, REQORSA Immunogene Therapy, in combination with Merck Co Inc NYSE:MRKs Keytruda in patients with stage III or IV non-small cell lung cancer NSCLC, where disease progressed after treatment with Keytruda. The Austin, Texas-based clinical-stage gene therapy company said that in the first quarter of 2022, it plans to initiate its Acclaim-2 clinical trial, which is an open-label, multicenter Phase 12 clinical trial evaluating REQORSA in combination with Keytruda, for this patient population. 